S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
BDX · Becton, Dickinson and Co.
NEW YORK STOCK EXCHANGE, INC. - BOATS Real Time Price • USD
Becton Dickinson and Co (BDX)
NEW YORK STOCK EXCHANGE, INC.
Health Care
$194.31
+0.57
(+0.30%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$194.31
$192.81
$195.18
52-WEEK RANGE
$194.31
$127.59
$195.99
What's happening
- BDX is up 0.30% today, trading at $194.31. — Live quote
- It's trading within 3% of its 52-week high ($195.99). (Finnhub fundamentals)
- Volume today (52,763) is well below its 3-month average of 1,992,860. (Finnhub fundamentals)
- Reports earnings on 2026-11-05 (after market close), 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $3.23 actual vs. $3.17 estimated (+1.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 6
Hold 9
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (20 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
BDX
+27.02%
vs S&P 500
+14.25%
1-YEAR RETURN
BDX
+29.06%
vs S&P 500
+14.50%
6-MONTH RETURN
BDX
+25.18%
3-MONTH RETURN
BDX
+25.98%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$3.23
Est. $3.17
BEAT +1.8%
2026-04-26 (Q1 2026)
$2.90
Est. $2.80
BEAT +3.5%
2025-10-26 (Q4 2025)
$3.96
Est. $3.96
MISS -0.0%
2025-07-26 (Q3 2025)
$3.68
Est. $3.44
BEAT +7.1%
Valuation Measures & Ratios
Enterprise Value4$68.85B
Forward P/E513.82
PEG Ratio6-25.11
Price / Sales (TTM1)2.53
Price / Book71.71
EV4 / Revenue3.30
EV4 / EBITDA15.95
Profit Margin4.52%
Operating Margin9.55%
Return on Equity (ROE8)3.80%
Return on Assets (ROA9)1.78%
Avg Volume (3M)1,992,860
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Dec '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $41.40B | $43.48B | $42.64B | $37.71B | $49.96B |
| P/E | 40.51 | 45.63 | 27.21 | 22.55 | 30.56 |
| Price/Sales | 2.10 | 2.27 | 2.17 | 1.95 | 2.54 |
| Price/Book | 1.70 | 1.80 | 1.69 | 1.48 | 1.98 |
| EV/Revenue | 2.75 | 2.99 | 3.00 | 2.81 | 3.40 |
| EV/EBITDA | 12.42 | 14.04 | 13.10 | — | — |
| ROE | 4.19% | 3.95% | 6.20% | 6.56% | 6.48% |
| ROA | 2.01% | 1.87% | 2.86% | 3.05% | 3.00% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short9,775,719
Change from Prior Settlement-13.61%
% of Float—
Days to Cover (Short Ratio)4.88
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +29.1%. Finnhub market metrics ↗
- Latest SEC filing is Form 4, filed 2026-09-29; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -9.6% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 4.5%. Finnhub fundamentals ↗
- Trailing P/E is 56.0, a high price relative to reported earnings. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on BDX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Dec '25 | Jun '25 | Mar '25 | Dec '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.98B | $4.71B | $5.25B | $4.73B | $4.48B | $5.17B | $4.99B | $5.04B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $663.0M | $93.0M | $552.0M | $739.0M | $383.0M | $453.0M | $602.0M | $734.0M |
| Net income | $377.0M | -$311.0M | $382.0M | $574.0M | $308.0M | $303.0M | $487.0M | $537.0M |
| EPS (diluted) | $1.37 | $-1.11 | $1.34 | $2.00 | $1.07 | $1.04 | $1.68 | $1.85 |
| EPS (basic) | $1.37 | $-1.11 | $1.34 | $2.00 | $1.07 | $1.05 | $1.68 | $1.85 |
| Operating margin | $13 | $2 | $11 | $16 | $9 | $9 | $12 | $15 |
| Net margin | $8 | -$7 | $7 | $12 | $7 | $6 | $10 | $11 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $50.73B | $50.83B | $54.84B | $55.33B | $54.90B | $54.47B | $54.66B | $57.29B |
| Stockholders' equity | $24.42B | $24.13B | $25.28B | $25.39B | $25.47B | $25.24B | $25.20B | $25.89B |
| Total current assets | $8.14B | $8.01B | $9.19B | $9.26B | $9.00B | $8.67B | $8.66B | $10.47B |
| Total current liabilities | $9.40B | $8.51B | $8.76B | $8.31B | $8.16B | $7.69B | $7.66B | $8.96B |
| Cash & equivalents | $708.0M | $813.0M | $740.0M | $567.0M | $735.0M | $667.0M | $711.0M | $1.72B |
| Accounts receivable | $2.36B | $2.21B | $2.51B | $2.40B | $2.94B | $3.03B | $2.64B | $3.03B |
| Inventory | $3.32B | $3.36B | $4.08B | $3.15B | $3.95B | $3.72B | $3.86B | $3.84B |
| Other current assets | $1.59B | $1.43B | $1.56B | $1.38B | $1.28B | $1.15B | $1.33B | $1.29B |
| Property, plant & equipment | $6.08B | $6.08B | $6.97B | $6.38B | $6.82B | $6.65B | $6.60B | $6.82B |
| Goodwill | $25.94B | $25.95B | $26.62B | $25.96B | $26.60B | $26.44B | $26.33B | $26.46B |
| Intangible assets | $8.02B | $8.35B | $9.01B | $9.23B | $9.77B | $10.12B | $10.47B | $10.87B |
| Other non-current assets | $2.55B | $2.43B | $3.04B | $2.38B | $2.70B | $2.58B | $2.59B | $2.62B |
| Accounts payable | — | — | — | $1.97B | — | — | — | $1.90B |
| Accrued liabilities | — | — | — | $3.10B | — | — | — | $3.48B |
| Short-term debt | — | — | — | $1.0M | — | — | — | $1.0M |
| Long-term debt | $13.51B | $14.71B | $16.92B | $17.62B | $17.53B | $17.67B | $17.44B | $17.94B |
| Other non-current liabilities | $2.39B | $2.46B | $2.81B | $2.63B | $2.83B | $3.00B | $3.42B | $3.56B |
| Common stock & paid-in capital | $371.0M | $371.0M | $371.0M | $371.0M | $371.0M | $371.0M | $371.0M | $371.0M |
| Retained earnings | $17.51B | $17.39B | $16.70B | $16.62B | $16.43B | $16.15B | $16.14B | $16.14B |
| Accumulated other comprehensive income (loss) | -$1.65B | -$1.76B | -$1.86B | -$1.90B | -$1.81B | -$1.72B | -$1.68B | -$1.73B |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | — | $657.0M | — | — | — | $693.0M | — |
| Investing cash flow | — | — | -$183.0M | -$494.0M | -$336.0M | -$192.0M | $204.0M | -$3.94B |
| Financing cash flow | — | — | -$302.0M | -$809.0M | -$841.0M | -$39.0M | -$1.93B | $124.0M |
| Free cash flow | — | — | $549.0M | — | — | — | $588.0M | — |
| Capital expenditures | $143.0M | $125.0M | $108.0M | $377.0M | $164.0M | $114.0M | $105.0M | $296.0M |
| Depreciation & amortization | $564.0M | $563.0M | $614.0M | $1.85B | $575.0M | $567.0M | $607.0M | $586.0M |
| Share-based compensation | $55.0M | $58.0M | $91.0M | $79.0M | $48.0M | $41.0M | $90.0M | $51.0M |
| Deferred income taxes | — | — | — | -$474.0M | — | — | — | -$211.0M |
| Change in inventory | — | — | — | $410.0M | — | — | — | -$98.0M |
| Purchases of investments | — | — | — | — | — | — | — | -$409.0M |
| Other investing activities | $81.0M | $36.0M | $75.0M | $213.0M | $131.0M | $42.0M | $94.0M | $126.0M |
| Dividends paid | $286.0M | $290.0M | $299.0M | — | $299.0M | $298.0M | $302.0M | — |
| Share repurchases | $0 | $2.00B | $250.0M | $250.0M | $0 | $0 | $750.0M | $0 |
| Debt issued | — | — | — | $0 | — | — | — | $4.52B |
| Debt repaid | $2.00B | $2.00B | $0 | $581.0M | $333.0M | $0 | $875.0M | $0 |
| Other financing activities | -$7.0M | $6.0M | -$69.0M | -$4.0M | -$2.0M | -$5.0M | -$76.0M | -$1.0M |
Income statement
| Line item | Sep '25 | Sep '24 | Sep '23 | Sep '22 | Sep '21 |
|---|---|---|---|---|---|
| Revenue | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B |
| Gross profit | — | — | — | — | — |
| Operating income | $2.58B | $2.40B | $2.11B | $2.28B | $2.25B |
| Net income | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B |
| EPS (diluted) | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 |
| EPS (basic) | $5.83 | $5.88 | $4.97 | $5.93 | $6.92 |
| Operating margin | $12 | $12 | $11 | $12 | $12 |
| Net margin | $8 | $8 | $8 | $9 | $11 |
Balance sheet
| Line item | Sep '25 | Sep '24 | Sep '23 | Sep '22 | Sep '21 |
|---|---|---|---|---|---|
| Total assets | $55.33B | $57.29B | $52.78B | $52.93B | $53.87B |
| Stockholders' equity | $25.39B | $25.89B | $25.80B | $25.28B | $23.68B |
| Total current assets | $9.26B | $10.47B | $8.68B | $8.14B | $8.84B |
| Total current liabilities | $8.31B | $8.96B | $6.64B | $7.81B | $6.63B |
| Cash & equivalents | $641.0M | $1.72B | $1.42B | $1.01B | $2.28B |
| Accounts receivable | $2.99B | $3.03B | $2.53B | $2.19B | $2.35B |
| Inventory | $3.89B | $3.84B | $3.27B | $3.22B | $2.74B |
| Other current assets | $1.51B | $1.29B | $1.38B | $1.56B | $1.05B |
| Property, plant & equipment | $7.00B | $6.82B | $6.56B | $6.01B | $6.00B |
| Goodwill | $26.61B | $26.46B | $24.52B | $24.62B | $23.89B |
| Intangible assets | $9.39B | $10.87B | $10.90B | $12.26B | $12.73B |
| Other non-current assets | $3.06B | $2.62B | $2.08B | $1.85B | $1.95B |
| Accounts payable | $1.97B | $1.90B | $1.64B | $1.70B | $1.74B |
| Accrued liabilities | $3.10B | $3.48B | $2.60B | $2.60B | $2.87B |
| Short-term debt | $1.0M | $1.0M | $0 | — | $0 |
| Long-term debt | $17.62B | $17.94B | $14.74B | $13.89B | $17.11B |
| Other non-current liabilities | $2.93B | $3.56B | $4.58B | $5.05B | $5.21B |
| Common stock & paid-in capital | $371.0M | $371.0M | $371.0M | $365.0M | $365.0M |
| Retained earnings | $16.62B | $16.14B | $15.54B | $15.16B | $13.83B |
| Accumulated other comprehensive income (loss) | -$1.90B | -$1.73B | -$1.55B | -$1.49B | -$2.09B |
Cash flow
| Line item | Sep '25 | Sep '24 | Sep '23 | Sep '22 | Sep '21 |
|---|---|---|---|---|---|
| Operating cash flow | — | — | — | — | $4.65B |
| Investing cash flow | -$818.0M | -$5.51B | -$716.0M | — | -$1.88B |
| Financing cash flow | -$3.62B | $2.09B | -$1.96B | — | -$3.31B |
| Free cash flow | — | — | — | — | $3.45B |
| Capital expenditures | $760.0M | $725.0M | $874.0M | $973.0M | $1.19B |
| Depreciation & amortization | $2.46B | $2.29B | $2.29B | $2.23B | $2.23B |
| Share-based compensation | $258.0M | $247.0M | $259.0M | $233.0M | $229.0M |
| Deferred income taxes | -$474.0M | -$211.0M | -$622.0M | -$129.0M | -$280.0M |
| Change in inventory | $410.0M | -$98.0M | $15.0M | $631.0M | $83.0M |
| Purchases of investments | — | $421.0M | $0 | $0 | — |
| Other investing activities | $480.0M | $444.0M | $382.0M | $178.0M | $142.0M |
| Share repurchases | $1.00B | $500.0M | $0 | $500.0M | $1.75B |
| Debt issued | $0 | $4.52B | $1.66B | $497.0M | $4.87B |
| Debt repaid | $1.79B | $1.14B | $2.15B | $805.0M | $5.11B |
| Other financing activities | -$87.0M | -$89.0M | -$120.0M | -$77.0M | -$265.0M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding BDX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-02 to 2026-09-28
Recent transactions
- Insiders have net sold 12,094 shares over the last 182 days, across 0 purchases and 11 sales.
- Most recent: Feld Michael (EVP, Chief Revenue Officer) — Open market sale of 76 shares on 2026-09-28.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)12,094 sh(11 txns)
Net Shares-12,094
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Feld Michael | EVP, Chief Revenue Officer | Open market sale | 2026-09-28 | 76 |
| Roque Vitor | EVP & Chief Financial Officer | Tax withholding | 2026-09-02 | 190 |
| Polen Thomas E Jr | Chairman, CEO and President | Option exercise | 2026-08-13 | 43,278 |
| Goette Roland | EVP and President, EMEA | Open market sale | 2026-08-11 | 2,438 |
| Muhsin Bilal | EVP & President Connected Care | Tax withholding | 2026-07-02 | 1,935 |
| Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Open market sale | 2026-06-24 | 1,100 |
| Menziuso Peter | EVP and President, BDI | Grant / award | 2026-06-01 | 14,258 |
| Neal Shana Carol | EVP and Chief People Officer | Tax withholding | 2026-04-06 | 1,146 |
| Minnix Lanesha | EVP and General Counsel | Grant / award | 2026-03-16 | 7,492 |
| Spikner Pamela L. | SVP Controller & CAO | Grant / award | 2026-03-02 | 931 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-28 | Feld Michael | EVP, Chief Revenue Officer | Open market sale | 76 | $183.70 |
| 2026-09-02 | Roque Vitor | EVP & Chief Financial Officer | Tax withholding | 190 | $0.00 |
| 2026-08-26 | Feld Michael | EVP, Chief Revenue Officer | Open market sale | 165 | $188.49 |
| 2026-08-20 | Feld Michael | EVP, Chief Revenue Officer | Tax withholding | 1,049 | $0.00 |
| 2026-08-13 | Polen Thomas E Jr | Chairman, CEO and President | Option exercise | 43,278 | $167.25 |
| 2026-08-13 | Polen Thomas E Jr | Chairman, CEO and President | Disposition to issuer | 39,126 | $185.00 |
| 2026-08-13 | Polen Thomas E Jr | Chairman, CEO and President | Open market sale | 4,152 | $185.00 |
| 2026-08-11 | Goette Roland | EVP and President, EMEA | Open market sale | 2,438 | $180.84 |
| 2026-07-27 | Feld Michael | EVP, Chief Revenue Officer | Open market sale | 75 | $157.13 |
| 2026-07-02 | Muhsin Bilal | EVP & President Connected Care | Tax withholding | 1,935 | $0.00 |
| 2026-07-01 | Muhsin Bilal | EVP & President Connected Care | Grant / award | 14,342 | $0.00 |
| 2026-06-26 | Feld Michael | EVP, Chief Revenue Officer | Open market sale | 75 | $152.80 |
| 2026-06-24 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Open market sale | 1,100 | $145.66 |
| 2026-06-10 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Open market sale | 1,100 | $151.48 |
| 2026-06-01 | Polen Thomas E Jr | Chairman, CEO and President | Option exercise | 20,209 | $126.16 |
| 2026-06-01 | Polen Thomas E Jr | Chairman, CEO and President | Disposition to issuer | 17,445 | $146.15 |
| 2026-06-01 | Polen Thomas E Jr | Chairman, CEO and President | Open market sale | 2,764 | $146.35 |
| 2026-06-01 | Menziuso Peter | EVP and President, BDI | Grant / award | 14,258 | $0.00 |
| 2026-05-26 | Feld Michael | EVP, Chief Revenue Officer | Open market sale | 75 | $147.35 |
| 2026-05-07 | Roque Vitor | EVP & Chief Financial Officer | Grant / award | 1,721 | $0.00 |
| 2026-04-27 | Feld Michael | EVP, Chief Revenue Officer | Open market sale | 74 | $151.94 |
| 2026-04-06 | Neal Shana Carol | EVP and Chief People Officer | Tax withholding | 1,146 | $0.00 |
| 2026-03-26 | Feld Michael | EVP, Chief Revenue Officer | Open market sale | 75 | $156.83 |
| 2026-03-16 | Minnix Lanesha | EVP and General Counsel | Grant / award | 7,492 | $0.00 |
| 2026-03-02 | Roque Vitor | Interim CFO | Grant / award | 931 | $0.00 |
| 2026-03-02 | Spikner Pamela L. | SVP Controller & CAO | Grant / award | 931 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 03:40 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-29 | 4 | 2026-09-28 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-08-27 | 4 | 2026-08-26 | View on SEC.gov → |
| 2026-08-24 | 4 | 2026-08-20 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-13 | View on SEC.gov → |
| 2026-08-12 | 4 | 2026-08-11 | View on SEC.gov → |
| 2026-08-06 | 4 | 2026-08-06 | View on SEC.gov → |
| 2026-08-06 | 4 | 2026-08-06 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-28 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-07-22 | 8-K | 2026-07-19 | View on SEC.gov → |
Recent news
Headlines about BDX (Becton, Dickinson and Co.). Links open the publisher — we don’t host full articles.
-
Can Boston Scientific Stock Bounce Off This Support Again?
Yahoo · 2026-10-22 -
Becton, Dickinson and Company (BDX) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-21 -
Becton, Dickinson and Company (BDX) stock price, news, quote and history
Yahoo Finance UK · 2026-10-21 -
SpaceX earnings roundup, Meta earnings preview, and tech trade fears
Yahoo · 2026-10-21 -
DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line
Yahoo · 2026-10-21 -
BSX Set to Report Q3 Earnings: Will MedSurg Strength Aid Performance?
Yahoo · 2026-10-21 -
Ecolab Gears Up to Report Q3 Results: How to Play the Stock?
Yahoo · 2026-10-21 -
Should Becton Dickinson Stock Holders Look At Boston Scientific Instead?
Yahoo · 2026-10-20
No headlines in this category right now — try “All”.